X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Translational Oncology

期刊標題檢索 TRANSL ONCOL 最新評論: I have been working with editor for over a month now, but I don't know... (2024-11-19)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Translational Oncology]您好,您是該頁面的第 65725 位訪客。

期刊簡介
期刊名稱Translational Oncology Translational Oncology
LetPub Score
6.0
50 ratings
Rate

Reputation
6.9

Influence
5.1

Speed
6.8

期刊簡稱TRANSL ONCOL
ISSN1936-5233
h-index41
CiteScore
CiteScoreSJRSNIPCiteScore Rank
8.401.2631.035
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q175 / 404
Category: Medicine
Subcategory: Cancer Research
Q268 / 230

自引率 (2023-2024)2.20%自引率趨勢
掲載範囲
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
官方網站https://www.journals.elsevier.com/translational-oncology
在線稿件提交https://www.editorialmanager.com/TRANON
開放訪問Yes
出版商Neoplasia Press
主題領域Biochemistry, Genetics and Molecular Biology
出版國/地區UNITED STATES
發行頻率四半期刊行
創刊年2007
每年文章數227每年文章數趨勢
黃金OA百分比98.11%
OA Related Info
APC: Yes( USD2930; )
APC waiver:Check Notes
Other charges: No
Keywords: translational oncology、cancer、genetics、endocrinology、tumour
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardPeer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ178/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1936-5233%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據: Moderate
參考鏈接
相關期刊 【Translational Oncology】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Cancer CommunicationsH-index: 0

    CiteScore: 25.50
    CELLULAR ONCOLOGYH-index: 0

    CiteScore: 10.30
    Frontiers in OncologyH-index: 60

    CiteScore: 6.20
    Journal of Gastric CancerH-index: 22

    CiteScore: 4.30
    Molecular and Cellular OncologyH-index: 0

    CiteScore: 3.20
    Clinical and Experimental MorphologyH-index: 0

    CiteScore: 0.60
    Critical Reviews in OncogenesisH-index: 0

    CiteScore: 1.70
    International Journal of Medical BiochemistryH-index: 0

    CiteScore: 0.50
    Advances in Cancer Biology MetastasisH-index: 0

    CiteScore: 2.40
    學科內最受檢索的期刊 頁面查看次數
    Frontiers in Oncology415879
    Cancer Communications55531
    CELLULAR ONCOLOGY31537
    Journal of Gastric Cancer16502
    Molecular and Cellular Oncology4959
    Critical Reviews in Oncogenesis3599
    Clinical and Experimental Morphology2583
    Advances in Cancer Biology Metastasis758
    International Journal of Medical Biochemistry631
  •  

    Translational Oncology Translational Oncology
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Translational Oncology] 的評論撰寫評論
作者: 欧阳先生


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-11-19 06:45:56 評論於
I have been working with editor for over a month now, but I don't know what to do next.
(0) 讚! | 欧阳先生

作者: xxxx----


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-26 10:27:22 評論於
8.25 was rejected, it feels like being rejected once the DIP takes too long.
(0) 讚! | xxxx----

作者: xxxx-ljyf


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-22 08:39:44 評論於
8.1 Submission in the evening
8.9 Decision in progress
It has been ongoing until 8.22 with no changes, may I ask if any experts have encountered this situation?
(0) 讚! | xxxx-ljyf

作者: chentiantian


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2024-08-07 14:27:34 評論於
Absolutely trash journal, do not submit. Rejection delays for a month.
(0) 讚! | chentiantian

作者: 0.020


領域: 医学
審稿時間: 2.0 month(s)
結果: 拒稿


撰寫評論

2024-03-25 10:04:07 評論於
Absolutely garbage journal, do not submit. The review process is very fast, with the review completed in one month. After revisions, only minor changes are suggested. However, there is no reason provided for direct rejection. It is a waste of time
(0) 讚! | 0.020

作者: NKer


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-10 13:30:22 評論於
How is the situation with the original poster now?
(0) 讚! | NKer

作者: 三水


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-22 15:24:19 評論於
OP, how long has it been since your decision in process was submitted for review?
(1) 讚! | 三水

作者: Jamie0703


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-16 17:33:58 評論於
12-06 submitted
12-10 with editor
12-15 decision in process
I guess it will be a rejection, but it's too slow. What are they doing with "decision in process"? Just reject it
(2) 讚! | Jamie0703

作者: lishen0709


領域: 医学
審稿時間: 12.0 month(s)
結果: 修改後接受


撰寫評論

2023-11-06 18:10:16 評論於
Mid-July: I'm not sure if the editor was constantly pushing or for some other reason, the second round of the new reviewer I found suddenly accepted the review invitation, and that was it after clicking accept. After a few days of waiting, the editor sent the official notice of acceptance.

Overall, the speed of handling manuscripts for this journal is not fast (mine is a case in point, but looking at the speed of their other manuscripts, it is also quite average), but what makes us feel unhappy is the inefficiency of the editorial team in handling things
(0) 讚! | lishen0709

作者: lishen0709


領域: 医学
審稿時間: 12.0 month(s)
結果: 修改後接受


撰寫評論

2023-11-06 18:09:42 評論於
This journal was submitted at the end of July 22, accepted at the end of July 23, taking one year. Here is a rough timeline:

End of July: Submitted, with editor.

End of October: Under review (2 reviewers).

Middle of November: First round of review completed, 2 major revisions.

End of November: Re-submitted, with editor, then sent back to the original 2 reviewers.

Middle of January: Still under review, one reviewer completed the second round of review quickly (accepted), the other reviewer never accepted the invitation for the second round. We emailed the editor and were told to wait.

Middle of February: Still under review, the other reviewer still did not accept the invitation. Emailed editor again, editor promised to find another reviewer, a few days later the manuscript was sent to a new reviewer.

Early March: Second round results, 1 accepted, 1 major revision.

End of March: Submitted after major revision, under review again.

End of May: Still under review, the second reviewer selected for the second round disappeared and never accepted the invitation. Emailed editor again, and were told to wait
(0) 讚! | lishen0709

作者: 草莓妮妮


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-06 17:37:22 評論於
Indeed, it is a loss. Perhaps we can aim for a higher score.
(0) 讚! | 草莓妮妮

作者: 空格键


領域: 医学
審稿時間: 1.0 month(s)
結果: 直接被接受


撰寫評論

2022-03-21 21:13:20 評論於
Is there also direct reception?
(0) 讚! | 空格键

作者: hub


領域: 医学
審稿時間: 1.0 month(s)
結果: 直接被接受


撰寫評論

2022-02-15 23:42:19 評論於
Submitted for four days and was directly accepted, isn't it a loss?
(0) 讚! | hub

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Translational Oncology] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*